Abbott Laboratories

The Schwab U.S. Dividend Equity ETF (SCHD) increased its healthcare allocation to 18.5% during its yearly portfolio update, adding Abbott Laboratories and UnitedHealth Group. The fund gathered nearly $4 billion in the first quarter as investors poured a total of $24.1 billion into U.S. dividend-focused funds, marking the strongest quarterly start since 2022.

The Schwab U.S. Dividend Equity ETF (SCHD) is drawing renewed interest following its annual portfolio rebalance and a recent dividend distribution. The fund's strategic shift and income profile are being highlighted as key attractions for investors.

Danaher shares fell in extended trading Friday, closing near $212.58. The dip precedes a market holiday, with attention shifting to next week's key inflation report.

Boston Scientific shares recovered slightly after a recent sell-off, supported by new long-term data for its Farapulse ablation system. Investor focus now shifts to the upcoming CHAMPION-AF trial results expected in late March.

Boston Scientific stock fell 2.6% in Monday trading, continuing last week's selloff as investors scrutinize the company's heart-rhythm device segment and Watchman demand.

Abbott Laboratories stock rose 1.6% Friday following a director's $1.09 million share purchase and new clinical data for its heart rhythm devices presented at a medical symposium.

Abbott shares rose 1.6% to $110.83 Friday but remain 21.5% below their 52-week high. The FDA updated a Class I recall for FreeStyle Libre 3 sensors, citing 860 serious injuries and seven deaths, while an insider purchased 10,000 shares.

AbbVie stock rose 2% Friday, ending a turbulent week marked by earnings scrutiny and a Moody's credit rating upgrade. Investors remain focused on Skyrizi and Rinvoq growth amid competitive pressures.

Johnson & Johnson shares gained 0.9% following a New Jersey appeals court decision to remove Beasley Allen from state talc cases and the release of early 12-month data for its investigational AFib device.